161 completed, 20 unknown, 17 recruiting, 11 terminated. 220 Phase 1, 34 Phase 2.
Follow Type 2 Diabetes: new trials by email Literature Review of Type 2 Diabetes trials Research Report on Type 2 Diabetes
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Evaluation of Superiority of Valsartan+Celecoxib+Metformin Over Metformin Alone in Type 2 Diabetes Patients Metformin, Val, Cel and Met XR Low, Val, Cel and Met XR High - Type 2 Diabetes, High Blood Pressure | Phase 1 / Phase 2 | Withdrawn | ARKAY Therapeutics | 2026-12-10 | 2026-07-16 | |
| Relacorilant in Patients With Poorly Controlled Type 2 Diabetes and Autonomous Cortisol Secretion Relacorilant - Type 2 Diabetes, Hypercortisolism | Phase 1 / Phase 2 | Not yet recruiting | The University of Texas Health Science Center at San Antonio | 34 | 2026-12-01 | 2026-11-09 |
| A Research Study Investigating How Adults With Overweight or Obesity, With or Without Type 2 Diabetes, Tolerate Switching to a New Treatment (Zenagamtide) From Their Current Tirzepatide Medication Tirzepatide, Zenagamtide - Overweight, Obesity | Phase 1 | Recruiting | Novo Nordisk A/S | 60 | 2026-10-08 | 2026-10-16 |
| A Research Study Investigating How Adults With Overweight or Obesity, With or Without Type 2 Diabetes, Tolerate Switching to a New Treatment (Zenagamtide) From Their Current Semaglutide Medication Semaglutide, Zenagamtide - Overweight, Obesity | Phase 1 | Recruiting | Novo Nordisk A/S | 60 | 2026-10-05 | 2026-10-16 |
| Alpelisib Challenge Test (ACT) Alpelisib 300 mg, Alpelisib Challenge Test (ACT): Mixed Meal Tolerance Test (MMTT) after taking alpelisib, Hyperglycemic clamp - Insulin Resistance, Type 2 Diabetes | Phase 1 | Recruiting | Columbia University | 15 | 2026-09-02 | 2026-09-03 |
| A Study on the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of HRS-1596 Tablets in Healthy Participants With a Single Dose and in Obese Participants With Multiple Doses HRS-1596, HRS-1596 Placebo - Weight Management, Type 2 Diabetes | Phase 1 | Not yet recruiting | Fujian Shengdi Pharmaceutical Co., Ltd. | 122 | 2026-09-01 | 2026-09-25 |
| A Three-part First-in-human Trial to Assess Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of GUB-UCN2 in Healthy Lean and Obese Participants and Participants With T2D GUB-UCN2, Placebo - Obesity, Type 2 Diabetes | Phase 1 / Phase 2 | Recruiting | Gubra A/S | 188 | 2026-07-27 | 2026-09-10 |
| A Clinical Study to Evaluate the Effect of Different Dosing Conditions on the Pharmacokinetics of HRS9531 Tablets in Healthy Participants HRS9531 tablets - Weight Management, Type 2 Diabetes | Phase 1 | Not yet recruiting | Fujian Shengdi Pharmaceutical Co., Ltd. | 100 | 2026-07-01 | 2026-06-24 |
| SGLT2i, Pioglitazone, and Ketone Production in T2D Empagliflozin 25 MG, Pioglitazone 15 mg increased to 30 mg after 2 weeks plus Empagliflozin Placebo, Empagliflozin 25 mg/d plus Pioglitazone (15/30 mg/d) - Type 2 Diabetes | Phase 1 | Recruiting | The University of Texas Health Science Center at San Antonio | 64 | 2026-05-11 | 2026-07-17 |
| A Phase 1 Clinical Trial to Assess the Safety of DWRX5003 and Relative Bioavailability to DWC202502 and DWC202503 in Healthy Adult Volunteers DWRX5003, DWC202502, DWC202503 - Obesity & Overweight, Type 2 Diabetes | Phase 1 | Recruiting | Daewoong Pharmaceutical Co. LTD. | 72 | 2026-05-06 | 2026-07-16 |
| A Food-Effect Study of CX11 in Healthy Participants CX11 (VCT220) - Obesity & Overweight, Type 2 Diabetes | Phase 1 | Completed | Vincentage Pharma Co., Ltd | 32 | 2026-03-04 | 2026-10-13 |
| Bioequivalence Study to Compare Imeglimin HCl 500 mg Film Coated Tablets Versus Twymeeg Tablets 500 mg Imeglimin Hydrochloride Film Coated Tablet, TWYMEEG® Tablets - Type 2 Diabetes | Phase 1 | Completed | Humanis Saglık Anonim Sirketi | 40 | 2026-02-06 | 2026-07-08 |
| A Study of PATAS Using Single Ascending Doses in Healthy Volunteers and Multiple Ascending Doses in Diabetic Subjects PATAS Trifluoroacetate, Placebo - Type 2 Diabetes | Phase 1 | Recruiting | AdipoPharma LLC | 56 | 2026-01-27 | 2026-09-29 |
| A Phase 1, Multiple Ascending Dose Study to Evaluate HMS1005 in Participants With Type 2 Diabetes HMS1005, Matching placebo - Type 2 Diabetes | Phase 1 | Recruiting | Hua Medicine Limited | 40 | 2025-12-04 | 2026-05-06 |
| A Research Study of a New Medicine, NNC9733-0001, in Healthy Participants and Participants With Type 2 Diabetes NNC9733-0001, Placebo - Healthy Volunteer, Type 2 Diabetes | Phase 1 | Recruiting | Novo Nordisk A/S | 60 | 2025-11-25 | 2026-07-20 |
| Study to Assess Safety, Tolerability, PK, and PD of Multiple Doses of ZE63-0302 Administrated Orally in T2DM Patients. ZE63-0302, Placebo - Type 2 Diabetes | Phase 1 | Completed | Eilean Therapeutics | 60 | 2025-11-19 | 2026-11-10 |
| Clinical Study to Evaluate the Pharmacokinetics and Safety of CKD-383 0.25/12.5/1000mg in Healthy Volunteers CKD-383 0.25/12.5/1000mg, CKD-501, D745, D150 - Type 2 Diabetes | Phase 1 | Completed | Chong Kun Dang Pharmaceutical | 30 | 2025-10-30 | 2025-12-26 |
| Clinical Study to Evaluate the Pharmacokinetics and Safety of CKD-383 0.5/10/1000mg in Healthy Volunteers CKD-383 0.5/10/1000mg, CKD-501, D744, D150 - Type 2 Diabetes | Phase 1 | Completed | Chong Kun Dang Pharmaceutical | 30 | 2025-10-28 | 2025-12-26 |
| Clinical Study to Evaluate the Pharmacokinetics and Safety of CKD-383 0.5/25/1000mg in Healthy Volunteers CKD-383 0.5/25/1000mg, CKD-501, D745, D150 - Type 2 Diabetes | Phase 1 | Completed | Chong Kun Dang Pharmaceutical | 31 | 2025-10-24 | 2025-12-26 |
| Assessing Gut Microbiome Changes Before and After an Oral Nutritional Supplement Intake Using the SIMBA Capsule in Diabetic Participants Oral nutritional supplement - Type 2 Diabetes | Phase 1 | Not yet recruiting | Nimble Science Ltd. | 30 | 2025-09-01 | 2025-08-11 |
Showing 20 of 220. Sign in to see all of them.
Diabetes Mellitus, Type 2 (220) · Obesity (25) · Diabetes Mellitus (16) · Insulin Resistance (15) · Overweight (14) · Hypertension (3) · Metabolic Diseases (3) · Weight Loss (3) · Body Weight (2) · Cardiovascular Diseases (2) · Diabetes Mellitus, Type 1 (2) · Dyslipidemias (2) · Inflammation (2) · Motor Activity (2) · Renal Insufficiency, Chronic (2)
Nutritional and Metabolic Diseases (220) · Endocrine System Diseases (219) · Glucose Metabolism Disorders (219) · Metabolic Diseases (217) · Diabetes Mellitus (204) · Pathological Conditions, Signs and Symptoms (30) · Nutrition Disorders (25) · Signs and Symptoms (25) · Overnutrition (24) · Body Weight (23) · Hyperinsulinism (15) · Overweight (11) · Cardiovascular Diseases (5) · Vascular Diseases (5) · Behavior (4)
Metformin (25) · Sitagliptin Phosphate (11) · lobeglitazone (7) · AZD1656 (6) · Exenatide (5) · empagliflozin (5) · henagliflozin (5) · semaglutide (5) · 3-((6-(ethylsulfonyl)-3-pyridinyl)oxy)-5-(2-hydroxy-1-methylethoxy)-N-(1-methyl-1H-pyrazol-3-yl)benzamide (3) · Exercise (3) · Glucagon-Like Peptide 1 (3) · Liraglutide (3) · Pioglitazone (3) · Simvastatin (3) · Sodium Chloride (3)
Jiangsu HengRui Medicine Co., Ltd. (20) · AstraZeneca (19) · Merck Sharp & Dohme LLC (13) · Novo Nordisk A/S (9) · Chong Kun Dang Pharmaceutical (8) · Fujian Shengdi Pharmaceutical Co., Ltd. (7) · Boryung Pharmaceutical Co., Ltd (5) · Eli Lilly and Company (4) · Gan and Lee Pharmaceuticals, USA (4) · Sunshine Lake Pharma Co., Ltd. (4) · The University of Texas Health Science Center at San Antonio (4) · Torrent Pharmaceuticals Limited (4) · Hanoi Medical University (3) · Sandoz (3) · Shandong Suncadia Medicine Co., Ltd. (3)
United States (56) · China (52) · Germany (18) · South Korea (17) · India (8) · Canada (7) · Australia (4) · Denmark (4) · Japan (4) · New Zealand (4) · Mexico (3) · Sweden (3) · Vietnam (3) · Singapore (2) · United Kingdom (2)
Ralph DeFronzo, MD (4) · Marcus Hompesch, MD (3) · Anhye Kim, Ph.D (2) · K Segal, PhD (2) · Klas Malmberg, MD, PhD (2) · Klas Malmberg, MD, PhD, Prof. (2) · Liyuan Zhao, Ph.D (2)
PMID 15220351, PMID 17098321, PMID 17283239, PMID 18957534, PMID 19433800, PMID 19691426, PMID 19698154, PMID 19706990, PMID 20185734, PMID 20357371, PMID 20357372, PMID 20923244, PMID 21048706, PMID 21169160, PMID 21949230, PMID 22668067, PMID 22699287, PMID 23010558, PMID 23578605, PMID 23837842, PMID 24712564, PMID 25030779, PMID 25136536, PMID 25344620, PMID 25651730, PMID 26084343, PMID 26153271, PMID 27143183, PMID 27392483, PMID 27743903, PMID 28096259, PMID 30346099, PMID 30593607, PMID 30607464, PMID 35363252, PMID 35750681, PMID 35871497, PMID 36526947, PMID 36883362, PMID 37034122, PMID 38651744, PMID 38700326, PMID 39708086, PMID 41020378, PMID 42320483, PMID 42573729, PMID 42764407, PMID 42829171, PMID 5425915, PMID 5626114
R01DK024092 (3), 2019 (2), 2025 (1), K23DK140614 (1), P30DK097512 (1), R01DK059358 (1), R01DK061644 (1), R01DK097550 (1), R21NR018349 (1)